BRYCE RICHARD PAUL 4
4 · PUMA BIOTECHNOLOGY, INC. · Filed Feb 3, 2021
Insider Transaction Report
Form 4
BRYCE RICHARD PAUL
SR VP, CLINICAL RESEARCH & DEV
Transactions
- Sale
COMMON STOCK
2021-02-02$12.23/sh−415$5,076→ 69,664 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.2306 to $12.2480, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.